Diagnostic and clinical utility of comprehensive multigene panel testing for patients with neuropathy
Open Access
- 14 August 2024
- journal article
- research article
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 29 (3) , 363-367
Abstract
Background and Aims: Prior to next‐generation sequencing (NGS), the evaluation of a patient with neuropathy typically consisted of screening for acquired causes, followed by clinical genetic testing of PMP22, MFN2, GJB1, and MPZ in patients with a positive family history and symptom onset prior to age 50. In this study, we examined the clinical utility of NGS in a large cohort of patients analyzed in a commercial laboratory.Methods: A cohort of 6849 adult patients underwent clinician‐ordered peripheral neuropathy multigene panel testing ranging from 66 to 111 genes that included NGS and intragenic deletion/duplication analysis.Results: A molecular diagnosis was identified for 8.4% of the cohort (n = 573/6849). Variants in PMP22, MFN2, GJB1, MPZ, and TTR accounted for 73.8% of molecular diagnoses. Results had potential clinical actionability for 398 (69.5%) patients. Our results suggest that 225/573 (39.3%) of molecular diagnoses and 113/398 (28.4%) of clinical interventions would have been missed if the testing approach had been restricted to older guidelines.Interpretation: Our results highlight the need for expanded genetic testing guidelines that account for the increased number of genes associated with hereditary neuropathy, address the overlap of acquired and hereditary neuropathy, and provide broader access to genetic diagnosis for patients.Keywords
This publication has 15 references indexed in Scilit:
- Rates and Classification of Variants of Uncertain Significance in Hereditary Disease Genetic TestingJAMA Network Open, 2023
- Evidence‐based consensus guidelines for ALS genetic testing and counselingAnnals of Clinical and Translational Neurology, 2023
- The landscape of reported VUS in multi-gene panel and genomic testing: Time for a changeGenetics in Medicine, 2023
- Genetic testing and counseling for the unexplained epilepsies: An evidence‐based practice guideline of the National Society of Genetic CounselorsJournal of Genetic Counseling, 2022
- Sherloc: a comprehensive refinement of the ACMG–AMP variant classification criteriaGenetics in Medicine, 2017
- The allelic spectrum of Charcot–Marie–Tooth disease in over 17,000 individuals with neuropathyMolecular Genetics & Genomic Medicine, 2014
- Clinical implications of genetic advances in Charcot–Marie–Tooth diseaseNature Reviews Neurology, 2013
- Charcot‐marie‐tooth disease subtypes and genetic testing strategiesAnnals of Neurology, 2011
- Practice Parameter: The Evaluation of Distal Symmetric Polyneuropathy: The Role of Laboratory and Genetic Testing (An Evidence‐Based Review)PM&R, 2009
- Evaluation of distal symmetric polyneuropathy: The role of laboratory and genetic testing (an evidence‐based review)Muscle & Nerve, 2008